Today is SMA Awareness Day.
We are excited to share the news that a clinical trial of AVXS-101, the first experimental genetic treatment for spinal muscular atrophy, commenced in London this week.
Registration is now open for the NICE meeting on Spinraza which will be held at NICE Manchester office on Tuesday 23 October 2018.
Today NICE held a closed-door meeting dedicated to discussing challenges with nusinersen appraisal. Clinical experts as well as TreatSMA, SMA Support UK and MD UK were invited to present their views.
Deciding on which powerchair to get for your child, especially their first real one, can feel like a daunting task. A lot of SMA children who have the ability to control a powerchair from a young age start off with a Whizzybug which is a small motorised powerchair suitable for ages 2-5 (approximately), it gives them their first real taste of freedom and independence and the ability to join in and play with friends and family. It also prepares them for the next step in the powerchair world.
During yesterday’s Questions Time, Mary Glindon MP asked the Prime Minister about access to Spinraza.
This week we submitted our comments to the NHS consultation on newborn screening for spinal muscular atrophy. We were shocked to learn that NHS argues against introducing this procedure, and we strongly objected to their views.
We have submitted our comments to the draft NICE guidance on nusinersen.